Denileukin diftitox for the treatment of cutaneous T-cell lymphoma

References

• AbeniDFrontaniMSampognaF2005Circulating CD8+ lymphocytes, white blood cells, and survival in patients with mycosis fungoidesBr J Dermatol1533243016086743
   PubMed Web of Science ®Google Scholar
• BachaPWilliamsDPWatersC1988Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion proteinJ Exp Med167612223126255
   PubMed Web of Science ®Google Scholar
• CriscioneVDWeinstockMA2007Incidence of cutaneous T-cell lymphoma in the United States, 1973–2002Arch Dermatol1438545917638728
   PubMed Web of Science ®Google Scholar
• DangNHFayadLMcLaughlinP2007Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphomaBr J Hematol1385025
   PubMed Web of Science ®Google Scholar
• DuvicMCatherJMaizeJ1998DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T-cell lymphomaAm J Hematol5887909590158
   PubMed Web of Science ®Google Scholar
• DuvicM2006Optimizing denileukin diftitox (Ontak®) therapyHaematologica Reports35760
   Google Scholar
• FossFMBorkowskiTAGilliomM1994Chimeric fusion protein toxin DAB486-IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II studyBlood841765748080984
   PubMed Web of Science ®Google Scholar
• FossFMBachaPOsannKE2001Biological correlates of acute hypersensitivity events with DAB389IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedicationClin Lymphoma Myeloma1298302
   Google Scholar
• FossFDemierreMFDivenutiG2005A phase-1 trial of bexarotene and denileukin diftitox in patients with relapse or refractory cutaneous T-cell lymphomaBlood106454715811959
   PubMed Web of Science ®Google Scholar
• FossF2006Clinical experience with denileukin diftitoxSemin Oncol33S11616516670
   PubMed Web of Science ®Google Scholar
• GaffenSLLiuKD2004Overview of interleukin-2 function, production, and clinical applicationsCytokine281092315473953
   PubMed Web of Science ®Google Scholar
• GemmillR2006Cutaneous T-cell lymphomaSemin Oncol Nurs2290616720231
   PubMedGoogle Scholar
• GhoriFPolderKDPinter-BrownLC2006Thyrotoxicosis after Denileukin Diftitox Therapy in Patients with Mycosis FungoidesJ Clin Endocrinol Metab912205816595600
   PubMed Web of Science ®Google Scholar
• GorgunGFossF2002Immunomodulatory effects of RXR retinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitoxBlood100139940312149223
   PubMed Web of Science ®Google Scholar
• HabermannTMPittelkowMR2004Cutaneous T-cell lymphomaAbeloffClinical oncology3rd edChurchill LivingstoneChapter 113
   Google Scholar
• HeskethPCaguicoaPKahH1993Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphomaJ Clin Oncol111682908355035
   PubMed Web of Science ®Google Scholar
• HoffmanRBenzEJShattilSJ2005Cutaneous T-cell lymphomaHematology: basic principles and practice4th edPhiladelphiaElsevierChapter 81
   Google Scholar
• KimYHLiuHLMraz-GernhardS2003Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progressionArch Dermatol1398576612873880
   PubMed Web of Science ®Google Scholar
• KiyokawaTShironoKHattoriT1989Cytotoxicity of Interleukin-2 toxin toward lymphocytes from patients with adult T-cell leukemiaCancer Res49404262786749
   PubMed Web of Science ®Google Scholar
• KuzelTMRosenSTGordonLI1993Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: efficacy in mycosis fungoides and other non-Hodgkin’s lymphomaLeuk Lymphoma11369778124209
   PubMed Web of Science ®Google Scholar
• LeMaistreCFMeneghettiCRosenblumJ1992Phase 1 trial of interleukin-2 (IL-2) fusion toxin (DAB486-IL-2) in hematologic malignancies expressing the IL-2 receptorBlood102547541586707
   PubMed Web of Science ®Google Scholar
• LeMaistreCFCraigFEMeneghettiC1993Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancersCancer Res53393048358720
   PubMed Web of Science ®Google Scholar
• LeMaistreCFSalehMNKuzelTM1998Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2Blood913994059427692
   PubMed Web of Science ®Google Scholar
• Negro-VilarAPrinceHMDuvicM2008Efficacy and safety of denileukin diftitox in cutaneous T-cell lymphoma patients: integrated analysis of three large phase III trialsJ Clin Oncol26520 SupplAbstract 8551
   Google Scholar
• NicholsJFossFKuzelTM1997Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignanciesEur J Cancer335346
   Web of Science ®Google Scholar
• OlsenEDuvicMFrankelA2001Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphomaJ Clin Oncol193768811208829
   PubMed Web of Science ®Google Scholar
• PaulliMBertiE2004Cutaneous T-cell lymphomas (including rare subtypes). Current concepts IIHaematologica8913728815531460
   PubMed Web of Science ®Google Scholar
• ReGGWatersCPoissonL1996IL-2 receptor expression and sensitivity to diphtheria fusion toxin DAB389-IL-2 in cultured hematopoietic cellsCancer Res56259058653702
   PubMed Web of Science ®Google Scholar
• RosenSTQuerfeldC2006Primary cutaneous T-cell lymphomaBerlinerNLinkerCSchifferCASH Educational Book2006Washington D.CAmerican Society of Hematology32330
   Google Scholar
• RuddleJBHarperCAHönemanD2006A denileukin diftitox (Ontak) associated retinopathy?Br J Ophthalmol901070116854841
   PubMed Web of Science ®Google Scholar
• SalehMNLeMaistreCFKuzelTM1998Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoidesJ Am Acad Dermatol3963739674399
   PubMed Web of Science ®Google Scholar
• ScarisbrickJJ2006Staging and management of cutaneous T-cell lymphomaClin Exp Dermatol31181616487086
   PubMed Web of Science ®Google Scholar
• ShaoRHTianXGorgunG2002Arginine butyrate increases the cytotoxicity of DAB389IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ geneLeuk Res2610778312443879
   PubMed Web of Science ®Google Scholar
• WillemzeRJaffeESBurgG2005WHO-ERCT classification for cutaneous lymphomaBlood10537688515692063
   PubMed Web of Science ®Google Scholar
• WilliamsDPParkerKBachaP1987Diphtheria toxin receptor binding domain substitution with Interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion proteinProtein Eng149383334101
   PubMedGoogle Scholar
• WilliamsDPSniderCEStromTB1990Structure function analysis of IL-2 toxin (DAB486-IL-2): Fragment B sequences required for delivery of fragment A to the cytosol of target cellsJ Biol Chem2651188592195027
   PubMed Web of Science ®Google Scholar
• ZackheimHAminSKashaniM1999Prognosis in cutaneous T-cell lymphoma by skin stage: Long-term survival in 489 patientsJ Am Acad Dermatol404182510071312
   PubMed Web of Science ®Google Scholar